Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenxbio (RGNX) Cost of Revenue (2016 - 2024)

Regenxbio (RGNX) has 11 years of Cost of Revenue data on record, last reported at $6.3 million in Q4 2024.

  • For Q4 2024, Cost of Revenue fell 43.78% year-over-year to $6.3 million; the TTM value through Dec 2024 reached $33.6 million, down 9.8%, while the annual FY2024 figure was $33.6 million, 9.8% down from the prior year.
  • Cost of Revenue reached $6.3 million in Q4 2024 per RGNX's latest filing, down from $12.4 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $23.1 million in Q4 2021 and bottomed at $3.4 million in Q1 2020.
  • Average Cost of Revenue over 5 years is $10.6 million, with a median of $10.9 million recorded in 2023.
  • Peak YoY movement for Cost of Revenue: soared 11655.17% in 2020, then crashed 73.84% in 2023.
  • A 5-year view of Cost of Revenue shows it stood at $10.3 million in 2020, then skyrocketed by 124.8% to $23.1 million in 2021, then plummeted by 44.56% to $12.8 million in 2022, then dropped by 12.09% to $11.2 million in 2023, then plummeted by 43.78% to $6.3 million in 2024.
  • Per Business Quant database, its latest 3 readings for Cost of Revenue were $6.3 million in Q4 2024, $12.4 million in Q3 2024, and $10.6 million in Q2 2024.